{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:04:26Z","timestamp":1793037866005,"version":"4.5.0"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10637-025-01525-8","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T02:12:14Z","timestamp":1745979134000},"page":"466-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Navigating antibody\u2012drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3090-127X","authenticated-orcid":false,"given":"Tala","family":"Najdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Chartouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel","family":"Soueidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampig","family":"Kourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"10","key":"1525_CR1","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.3390\/molecules26102943","volume":"26","author":"S Baah","year":"2021","unstructured":"Baah S, Laws M, Rahman KM (2021) Antibody\u2013drug conjugates\u2014a tutorial review. Molecules 26(10):2943","journal-title":"Molecules"},{"key":"1525_CR2","unstructured":"Research C for DE and. FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer. FDA [Internet]. 2019 Dec 20 [cited 2024 Oct 5]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer"},{"key":"1525_CR3","unstructured":"Research C for DE and. FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer. FDA [Internet]. 2024 Aug 9 [cited 2024 Oct 5]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer"},{"issue":"1","key":"1525_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y (2022) Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther 7(1):93","journal-title":"Signal Transduct Target Ther"},{"key":"1525_CR5","unstructured":"Cancer Network [Internet]. 2013 [cited 2024 Oct 5]. FDA approves T-DM1 (Kadcyla) for HER2-positive breast cancer. Available from: https:\/\/www.cancernetwork.com\/view\/fda-approves-t-dm1-kadcyla-her2-positive-breast-cancer"},{"key":"1525_CR6","unstructured":"Research C for DE and. FDA approves ado-trastuzumab emtansine for early breast cancer. FDA [Internet]. 2024 Aug 9 [cited 2024 Oct 5]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ado-trastuzumab-emtansine-early-breast-cancer"},{"key":"1525_CR7","unstructured":"Research C for DE and. FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer. FDA [Internet]. 2023 Feb 3 [cited 2024 Oct 5]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sacituzumab-govitecan-hziy-hr-positive-breast-cancer"},{"key":"1525_CR8","unstructured":"Research C for DE and. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. FDA [Internet]. 2024 Aug 9 [cited 2024 Oct 5]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2"},{"issue":"12","key":"1525_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, Im SA, Park YH, Hegg R et al (2022) Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386(12):1143\u20131154","journal-title":"N Engl J Med"},{"key":"1525_CR10","unstructured":"Milligan L. Guidance for Industry. Clinical Pharmacology"},{"issue":"19","key":"1525_CR11","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783\u20131791","journal-title":"N Engl J Med"},{"issue":"7","key":"1525_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617\u2013628","journal-title":"N Engl J Med"},{"issue":"3","key":"1525_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","volume":"35","author":"C Saura","year":"2024","unstructured":"Saura C, Modi S, Krop I, Park YH, Kim SB, Tamura K et al (2024) Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol 35(3):302\u2013307","journal-title":"Ann Oncol"},{"issue":"10390","key":"1525_CR14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G et al (2023) Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401(10390):1773\u201385","journal-title":"Lancet"},{"issue":"10371","key":"1525_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V et al (2023) Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401(10371):105\u2013117","journal-title":"Lancet"},{"issue":"1","key":"1525_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9\u201320","journal-title":"N Engl J Med"},{"issue":"22","key":"1525_CR17","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA et al (2024) Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 391(22):2110\u20132122","journal-title":"N Engl J Med"},{"issue":"16","key":"1525_CR18","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384(16):1529\u20131541","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"1525_CR19","doi-asserted-by":"publisher","first-page":"LBA1001","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1001","volume":"40","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cortes J, Schmid P, Loirat D et al (2022) Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician\u2019s choice (TPC) in patients (Pts) with hormone receptor\u2013positive\/HER2-negative (HR+\/HER2-) advanced breast cancer. JCO 40(17_suppl):LBA1001","journal-title":"JCO"},{"key":"1525_CR20","unstructured":"The First Affiliated Hospital with Nanjing Medical University. Trastuzumab Emtansine (T-DM1) Treatment in HER2-positive breast cancer patients with progressive disease after TKIs or HP therapy: a multicenter, single-arm, phase II study [Internet]. clinicaltrials.gov; 2024 Apr [cited 2024 Oct 22]. Report No.: NCT06125834. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06125834"},{"key":"1525_CR21","unstructured":"Hoffmann-La Roche. An observational study to evaluate the safety and effectiveness of trastuzumab emtansine (T-DM1) as second- or later-line therapy in chinese patients with HER2 positive advanced breast cancer [Internet]. clinicaltrials.gov; 2024 Oct [cited 2024 Oct 22]. Report No.: NCT05945927. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05945927"},{"issue":"16_suppl","key":"1525_CR22","doi-asserted-by":"publisher","first-page":"e13005","DOI":"10.1200\/JCO.2024.42.16_suppl.e13005","volume":"42","author":"C Hao","year":"2024","unstructured":"Hao C, Qi X, Shi Y, Tong Z, Zhang J, Meng W et al (2024) Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): a single-arm phase II trial. JCO 42(16_suppl):e13005\u2013e13005","journal-title":"JCO"},{"key":"1525_CR23","unstructured":"Tianjin Medical University Cancer Institute and Hospital. A prospective, multicenter, phase II clinical study of trastuzumab and pyrotinib maleate in patients with HER2-positive metastatic breast cancer who had progressed on TKI therapy [Internet]. clinicaltrials.gov; 2022 Sep [cited 2024 Oct 23]. Report No.: NCT05560308. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05560308"},{"key":"#cr-split#-1525_CR24.1","unstructured":"Anders C (2024) Secondary brain metastases prevention after isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in patients with advanced Human epidermal growth factor receptor 2+ breast cancer with the addition of tucatinib [Internet]. clinicaltrials.gov"},{"key":"#cr-split#-1525_CR24.2","unstructured":"[cited 2024 Oct 22]. Report No.: NCT05323955. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05323955"},{"key":"#cr-split#-1525_CR25.1","unstructured":"Freedman R (2024) ATOP TRIAL: adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Internet]. clinicaltrials.gov"},{"key":"#cr-split#-1525_CR25.2","unstructured":"[cited 2024 Oct 23]. Report No.: NCT03587740. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03587740"},{"key":"1525_CR26","unstructured":"Memorial Sloan Kettering Cancer Center. A phase 2 trial of ado-trastuzumab emtansine for patients with HER2 amplified or mutant cancers [Internet]. clinicaltrials.gov; 2024 May [cited 2024 Oct 23]. Report No.: NCT02675829. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02675829"},{"key":"1525_CR27","unstructured":"M.D. Anderson Cancer Center. A phase II study of tucatinib and ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB) [Internet]. clinicaltrials.gov; 2024 Sep [cited 2024 Oct 23]. Report No.: NCT05673928. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05673928"},{"key":"1525_CR28","unstructured":"Consorzio Oncotech. Observational study of effectiveness and safety of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and anti-HER2 target therapy [Internet]. clinicaltrials.gov; 2023 Mar [cited 2024 Oct 22]. Report No.: NCT05754502. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05754502"},{"key":"1525_CR29","unstructured":"Regina Elena Cancer Institute. Tolerability and efficacy of adjuvant T-DM1 in patients with HER2 positive breast cancer after incomplete pathological response to neoadjuvant chemotherapy including anti-HER2 agents. Real-world Multicenter Retrospective-prospective Study. ATD-Study. [Internet]. clinicaltrials.gov; 2024 Sep [cited 2024 Oct 22]. Report No.: NCT06272799. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06272799"},{"key":"1525_CR30","unstructured":"Alliance for Clinical Trials in Oncology. The CompassHER2 Trials (comprehensive use of pathologic response assessment to optimize therapy in HER2-positive breast cancer) CompassHER2 residual disease (RD), a double-blinded, phase III randomized trial of T-DM1 compared with T-DM1 and tucatinib [Internet]. clinicaltrials.gov; 2024 Aug [cited 2024 Oct 22]. Report No.: NCT04457596. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04457596"},{"key":"1525_CR31","unstructured":"ECOG-ACRIN Cancer Research Group. (CompassHER2-pCR): preoperative THP and postoperative HP in patients who achieve a pathologic complete response [Internet]. clinicaltrials.gov; 2024 Apr [cited 2024 Oct 23]. Report No.: NCT04266249. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04266249"},{"key":"1525_CR32","unstructured":"Hoffmann-La Roche. A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for HER2-positive breast cancer at high risk of recurrence following preoperative therapy [Internet]. clinicaltrials.gov; 2024 Oct [cited 2024 Oct 23]. Report No.: NCT04873362. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04873362"},{"issue":"10","key":"1525_CR33","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","volume":"21","author":"LA Emens","year":"2020","unstructured":"Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB et al (2020) Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol 21(10):1283\u20131295","journal-title":"Lancet Oncol"},{"key":"1525_CR34","unstructured":"University Health Network, Toronto. Kadcyla and neratinib for interception of HER2+ breast cancer with molecular residual disease [Internet]. clinicaltrials.gov; 2023 Jul [cited 2024 Oct 23]. Report No.: NCT05388149. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05388149"},{"key":"#cr-split#-1525_CR35.1","unstructured":"Tolaney S (2024) A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for stage I HER2-positive breast cancer (ATEMPT 2.0) [Internet]. clinicaltrials.gov"},{"key":"#cr-split#-1525_CR35.2","unstructured":"[cited 2024 Oct 23]. Report No.: NCT04893109. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04893109"},{"issue":"0","key":"1525_CR36","first-page":"JCO.23.02170","volume":"0","author":"P Tarantino","year":"2024","unstructured":"Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ et al (2024) Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I human epidermal growth factor receptor 2\u2013positive breast cancer: 5-year results and correlative analyses from ATEMPT. JCO 0(0):JCO.23.02170","journal-title":"JCO"},{"key":"1525_CR37","unstructured":"Population Health Research Institute. Safety of continuing HER-2 directed therapy in overt left ventricular dysfunction: a randomized, controlled trial [Internet]. clinicaltrials.gov; 2024 Mar [cited 2024 Oct 23]. Report No.: NCT04680442. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04680442"},{"key":"1525_CR38","unstructured":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Trastuzumab deruxtecan (T-DXd): tailoring treatment and companion diagnostics (CDx) by liquid biopsy. DIAMOND STUDY [Internet]. clinicaltrials.gov; 2024 Apr [cited 2024 Oct 9]. Report No.: NCT05919212. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05919212"},{"key":"1525_CR39","unstructured":"SOLTI Breast Cancer Research Group. HER2-PREDICT: translational study of tumor samples from patients treated with trastuzumab deruxtecan (T-DXd; DS-8201a) [Internet]. clinicaltrials.gov; 2023 Jan [cited 2024 Oct 9]. Report No.: NCT04257162. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04257162"},{"issue":"33","key":"1525_CR40","doi-asserted-by":"publisher","first-page":"S656","DOI":"10.1016\/j.annonc.2022.07.299","volume":"1","author":"N Epaillard","year":"2022","unstructured":"Epaillard N, Lusque A, Pistilli B, Andr\u00e9 F, Bachelot T, Pierga JY et al (2022) 260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial. Ann Oncol 1(33):S656","journal-title":"Ann Oncol"},{"key":"1525_CR41","unstructured":"UNICANCER. Phase II, Open Label Study of DS-8201a, an Anti-HER2-antibody drug conjugate (ADC) for advanced breast cancer patients, with biomarkers analysis to characterize response/resistance to therapy [Internet]. clinicaltrials.gov; 2023 Dec [cited 2024 Oct 10]. Report No.: NCT04132960. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04132960"},{"key":"#cr-split#-1525_CR42.1","doi-asserted-by":"crossref","unstructured":"Zou Y (2024) HER2 heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer [Internet]. clinicaltrials.gov","DOI":"10.1016\/j.annonc.2024.10.059"},{"key":"#cr-split#-1525_CR42.2","unstructured":"[cited 2024 Oct 9]. Report No.: NCT06551220. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06551220"},{"key":"1525_CR43","unstructured":"Daiichi Sankyo. A multi-center prospective observational study to assess the effectiveness and safety of trastuzumab deruxtecan in Chinese breast cancer patients (REFRESH) [Internet]. clinicaltrials.gov; 2024 Sep [cited 2024 Oct 9]. Report No.: NCT06210776. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06210776"},{"key":"1525_CR44","doi-asserted-by":"crossref","unstructured":"AstraZeneca. Prospective non-interventional study (NIS) to examine patient-reported outcomes and real-world clinical data in patients with HER2-positive or HER2-low unresectable or metastatic breast cancer treated with trastuzumab deruxtecan [Internet]. clinicaltrials.gov; 2024 Oct [cited 2024 Oct 9]. Report No.: NCT05573893. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05573893","DOI":"10.1016\/j.esmoop.2024.103283"},{"key":"1525_CR45","unstructured":"H. Lee Moffitt Cancer Center and Research Institute. A pilot study of sequential ("First Strike, Second Strike") therapies, modeled on evolutionary dynamics of anthropocene extinctions, for hormone positive metastatic breast cancer [Internet]. clinicaltrials.gov; 2024 Sep [cited 2024 Oct 9]. Report No.: NCT06409390. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06409390"},{"key":"1525_CR46","unstructured":"Daiichi Sankyo. A phase 3b, multicenter, global, interventional, open-label study of trastuzumab deruxtecan (T-DXd), an anti-HER2-antibody drug conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15) [Internet]. clinicaltrials.gov; 2024 Sep [cited 2024 Oct 10]. Report No.: NCT05950945. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05950945"},{"key":"1525_CR47","unstructured":"Spanish Breast Cancer Research Group. Phase II trial of Trastuzumab deruxtecan in first-line treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients considered resistant to trastuzumab + pertuzumab + taxane due to early relapse."TRANSCENDER study" [Internet]. clinicaltrials.gov; 2024 Sep [cited 2024 Oct 9]. Report No.: NCT05744375. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05744375"},{"key":"1525_CR48","unstructured":"The Netherlands Cancer Institute. Basket study for oligo-metastatic breast cancer part 1: trastuzumab-deruxtecan for HER2-positive oligo-metastatic breast cancer [Internet]. clinicaltrials.gov; 2024 Aug [cited 2024 Oct 10]. Report No.: NCT05982678. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05982678"},{"key":"1525_CR49","unstructured":"ESMO. Substantial and durable overall and intracranial activity of trastuzumab deruxtecan in previously treated HER2-positive mBC including a large cohort of patients with brain metastases [Internet]. [cited 2024 Oct 30]. Available from: https:\/\/www.esmo.org\/oncology-news\/substantial-and-durable-overall-and-intracranial-activity-of-trastuzumab-deruxtecan-in-previously-treated-her2-positive-mbc-including-a-large-cohort-of-patients-with-brain-metastases"},{"key":"1525_CR50","unstructured":"AstraZeneca. An open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan in patients with or without baseline brain metastasis with previously treated advanced/metastatic HER2-positive breast cancer (DESTINY-Breast12) [Internet]. clinicaltrials.gov; 2024 Jul [cited 2024 Oct 10]. Report No.: NCT04739761. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04739761"},{"key":"1525_CR51","doi-asserted-by":"publisher","unstructured":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S et al (2024) Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases. Neuro Oncol:noae123. https:\/\/doi.org\/10.1093\/neuonc\/noae123","DOI":"10.1093\/neuonc\/noae123"},{"key":"1525_CR52","unstructured":"MedSIR. Phase II study of trastuzumab-deruxtecan (T-DXd; DS-8201a) in HER2-low breast cancer patients presenting with newly diagnosed or progressing brain metastases [Internet]. clinicaltrials.gov; 2024 Sep [cited 2024 Oct 10]. Report No.: NCT06048718. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06048718"},{"key":"1525_CR53","unstructured":"Bartsch R (2023) Phase II study of trastuzumab-deruxtecan (T-DX; DS-8201a) in HER2-positive breast cancer patients with newly diagnosed or progressing brain metastases [Internet]. clinicaltrials.gov; [cited 2024 Oct 9]. Report No.: NCT04752059. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04752059"},{"key":"1525_CR54","unstructured":"Beijing 302 Hospital. Efficacy and safety of T-Dxd in the treatment of HER2-positive breast cancer with brain metastases after prior pyrotinib treatment [Internet]. clinicaltrials.gov; 2023 Nov [cited 2024 Oct 10]. Report No.: NCT06135194. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06135194"},{"key":"#cr-split#-1525_CR55.1","unstructured":"Zhao J (2024) Open, controlled, multicenter phase I/II clinical study of hydroxychloroquine in combination with antibody-drug conjugate versus antibody-drug conjugate for advanced breast cancer. [Internet]. clinicaltrials.gov"},{"key":"#cr-split#-1525_CR55.2","unstructured":"[cited 2024 Oct 10]. Report No.: NCT06328387. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06328387"},{"key":"#cr-split#-1525_CR56.1","unstructured":"Zhang MDJ (2024) A prospective phase Ib study of anlotinib with trastuzumab deruxtecan for HER2-low unresectable and/or metastatic breast cancer (ALTER-BC-Ib-01) [Internet]. clinicaltrials.gov"},{"key":"#cr-split#-1525_CR56.2","unstructured":"[cited 2024 Oct 9]. Report No.: NCT06331169. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06331169"},{"key":"1525_CR57","unstructured":"M.D. Anderson Cancer Center. Phase 1b study of EZH1/2 Inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 Low/Ultra-low/null metastatic breast cancer [Internet]. clinicaltrials.gov; 2024 Oct [cited 2024 Oct 9]. Report No.: NCT05633979. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05633979"},{"key":"1525_CR58","unstructured":"QuantumLeap Healthcare Collaborative. PRE-investigation of serial studies to predict your therapeutic response with imaging and molecular analysis: a phase I/Ib platform trial [Internet]. clinicaltrials.gov; 2024 Oct [cited 2024 Oct 9]. Report No.: NCT05868226. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05868226"},{"key":"1525_CR59","unstructured":"DIA Global Forum [Internet]. 2021 [cited 2024 Oct 28]. I-SPY 2.2: evolving the I-SPY 2 TRIAL to adapt therapies for each patient and optimize outcome. Available from: https:\/\/globalforum.diaglobal.org\/issue\/july-2021\/i-spy-2-2-evolving-the-i-spy-2-trial-to-adapt-therapies-for-each-patient-and-optimize-outcome\/"},{"key":"1525_CR60","unstructured":"AstraZeneca. A Phase 1b Multicentre, Open-label, modular, dose-finding and dose-expansion study to explore the safety, tolerability, pharmacokinetics and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with metastatic HER2-low breast cancer (DESTINY-Breast08) [Internet]. clinicaltrials.gov; 2024 Aug [cited 2024 Oct 26]. Report No.: NCT04556773. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04556773"},{"key":"1525_CR61","unstructured":"AstraZeneca. A Phase 1b/2 Multicentre, open-label, modular, dose-finding and dose-expansion study to explore the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive metastatic breast cancer (DESTINY-Breast07) [Internet]. clinicaltrials.gov; 2024 Sep [cited 2024 Oct 30]. Report No.: NCT04538742. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04538742"},{"issue":"16_suppl","key":"1525_CR62","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/JCO.2022.40.16_suppl.3025","volume":"40","author":"F Andre","year":"2022","unstructured":"Andre F, Hamilton EP, Loi S, Im SA, Sohn J, Tseng LM et al (2022) Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced\/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC). JCO 40(16_suppl):3025","journal-title":"JCO"},{"key":"1525_CR63","unstructured":"Daiichi Sankyo. A phase 1b, multicenter, two-part, open-label study of trastuzumab deruxtecan (DS-8201a), an anti-human epidermal growth factor receptor-2 (HER2)-antibody drug conjugate (ADC), in combination with pembrolizumab, an anti-PD-1 antibody, for subjects with locally advanced/metastatic breast or non-small cell lung cancer (NSCLC) [Internet]. clinicaltrials.gov; 2024 Aug [cited 2024 Oct 9]. Report No.: NCT04042701. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04042701"},{"key":"1525_CR64","unstructured":"TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer. | Journal of Clinical Oncology [Internet]. [cited 2024 Oct 30]. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2022.40.16_suppl.TPS623"},{"key":"1525_CR65","unstructured":"Jonsson Comprehensive Cancer Center. A phase II, multicenter, open-label trial to evaluate the safety and efficacy of trastuzumab deruxtecan (DS-8201a) with or without anastrozole for HER2 low hormone receptor positive (HR+) breast cancer in the neoadjuvant setting [Internet]. clinicaltrials.gov; 2024 Sep [cited 2024 Oct 9]. Report No.: NCT04553770. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04553770"},{"key":"#cr-split#-1525_CR66.1","doi-asserted-by":"crossref","unstructured":"Foukakis T (2024) A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: ARIADNE [Internet]. clinicaltrials.gov","DOI":"10.1016\/j.annonc.2024.08.278"},{"key":"#cr-split#-1525_CR66.2","unstructured":"[cited 2024 Oct 10]. Report No.: NCT05900206. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05900206"},{"key":"#cr-split#-1525_CR67.1","unstructured":"Lynce F (2024) TRUDI: a phase II study of neoadjuvant trastuzumab deruxtecan and durvalumab for stage III, HER2-expressing inflammatory breast cancer [Internet]. clinicaltrials.gov"},{"key":"#cr-split#-1525_CR67.2","unstructured":"[cited 2024 Oct 9]. Report No.: NCT05795101. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05795101"},{"key":"1525_CR68","unstructured":"West German Study Group. Neoadjuvant dynamic marker - adjusted personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer [Internet]. clinicaltrials.gov; 2023 Sep [cited 2024 Oct 30]. Report No.: NCT05704829. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05704829"},{"key":"1525_CR69","unstructured":"Cancer Trials Ireland. Single arm phase 2 Trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a standard chemotherapy-sparing approach to curative-intent treatment - SHAMROCK study [Internet]. clinicaltrials.gov; 2024 Aug [cited 2024 Oct 10]. Report No.: NCT05710666. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05710666"},{"key":"1525_CR70","unstructured":"AstraZeneca. A phase 3 open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared to ddAC-THP in participants with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11) [Internet]. clinicaltrials.gov; 2024 Jul [cited 2024 Oct 10]. Report No.: NCT05113251. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05113251"},{"issue":"22","key":"1525_CR71","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1200\/JCO.22.01816","volume":"41","author":"N Harbeck","year":"2023","unstructured":"Harbeck N, Nitz UA, Christgen M, K\u00fcmmel S, Braun M, Schumacher C et al (2023) De-escalated neoadjuvant trastuzumab-emtansine with or without endocrine therapy versus trastuzumab with endocrine therapy in HR+\/HER2+ early breast cancer: 5-year survival in the WSG-ADAPT-TP trial. JCO 41(22):3796\u20133804","journal-title":"JCO"},{"key":"1525_CR72","unstructured":"Study Details | Real-world effectiveness and safety study of sacituzumab govitecan in Chinese metastatic breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 4]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06356519?term=real%20world&intr=Sacituzumab%20govitecan&rank=1"},{"key":"1525_CR73","unstructured":"Study Details | Biomarkers of efficacy and tolerability of sacituzumab-govitecan in the treatment of patients with triple-negative breast cancer in the metastatic phase: prospective multicenter real-world study | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06240195?term=BIO-PROSA&rank=1"},{"key":"1525_CR74","unstructured":"Study Details | HR+\/HER2- advanced or metastatic breast cancer patients treated with sacituzumab govitecan | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06236269?term=Sacituzumab&rank=16"},{"key":"1525_CR75","unstructured":"Study Details | Sequencing antibody drug conjugates in ER+\/HER2 LOW MBC | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06263543?term=Sacituzumab&rank=37"},{"key":"1525_CR76","unstructured":"Study Details | Sacituzumab govitecan +\/- pembrolizumab in HR+ \/ HER2 - MBC | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04448886?term=NCT04448886&rank=1"},{"key":"1525_CR77","unstructured":"Study Details | Sacituzumab govitecan +\/- pembrolizumab in metastatic TNBC | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04468061?term=Sacituzumab&rank=3"},{"issue":"17_suppl","key":"1525_CR78","doi-asserted-by":"publisher","first-page":"LBA1004","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1004","volume":"42","author":"AC Garrido-Castro","year":"2024","unstructured":"Garrido-Castro AC, Kim SE, Desrosiers J, Nanda R, Carey LA, Clark AS et al (2024) SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive\/HER2-negative breast cancer. JCO 42(17_suppl):LBA1004","journal-title":"JCO"},{"key":"1525_CR79","unstructured":"Study Details | Study to evaluate sacituzumab govitecan in combination with talazoparib in patients with metastatic breast cancer. | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04039230?term=Sacituzumab&rank=46"},{"issue":"16_suppl","key":"1525_CR80","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1200\/JCO.2024.42.16_suppl.1102","volume":"42","author":"RO Abelman","year":"2024","unstructured":"Abelman RO, Spring L, Niemierko A, Abraham E, McNeice M, Goff J et al (2024) Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): results from a phase II study. JCO 42(16_suppl):1102","journal-title":"JCO"},{"key":"1525_CR81","unstructured":"Study Details | Alpelisib and sacituzumab govitecan for treatment of breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05143229?term=Sacituzumab&rank=9#contacts-and-locations"},{"key":"1525_CR82","unstructured":"Study Details | A single-arm phase II trial of sacituzumab govitecan and trastuzumab for HER2+ metastatic breast cancer after trastuzumab deruxtecan (SATEEN) | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06100874?term=Sacituzumab&page=2&rank=62"},{"key":"1525_CR83","unstructured":"Study Details | Avelumab with binimetinib, sacituzumab govitecan, or liposomal doxorubicin in treating stage IV or unresectable, recurrent triple negative breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03971409?term=Sacituzumab&page=2&rank=77"},{"key":"1525_CR84","unstructured":"Study Details | Testing sacituzumab govitecan therapy in patients with HER2-negative breast cancer and brain metastases | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04647916?term=Sacituzumab&rank=15"},{"issue":"15","key":"1525_CR85","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M et al (2024) Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. JCO 42(15):1738\u20131744","journal-title":"JCO"},{"key":"1525_CR86","unstructured":"Study Details | Study of sacituzumab govitecan-hziy and pembrolizumab versus treatment of physician\u2019s choice and pembrolizumab in patients with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05382286?term=ASCENT-04%20NCT05382286%20%20&rank=1"},{"key":"1525_CR87","unstructured":"Study Details | Study of sacituzumab govitecan-hziy versus treatment of physician\u2019s choice in patients with previously untreated locally advanced inoperable or metastatic triple-negative breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05382299?term=Sacituzumab&page=3&rank=104"},{"key":"1525_CR88","unstructured":"West German Study Group. Neoadjuvant dynamic marker - adjusted personalized therapy comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab in low-risk, triple-negative early breast cancer (ADAPT-TN-III) [Internet]. clinicaltrials.gov; 2024 Feb [cited 2024 Oct 31]. Report No.: NCT06081244. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06081244"},{"key":"1525_CR89","unstructured":"Study Details | Sacituzumab govitecan in primary HER2-negative breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04595565?term=NCT04595565&rank=1"},{"issue":"33","key":"1525_CR90","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.1016\/j.annonc.2022.03.074","volume":"1","author":"F Marm\u00e9","year":"2022","unstructured":"Marm\u00e9 F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C et al (2022) 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment. Ann Oncol 1(33):S148\u2013S149","journal-title":"Ann Oncol"},{"key":"#cr-split#-1525_CR91.1","unstructured":"Mittendorf EA (2024) A single arm phase 2 trial of atezolizumab with sacituzumab govitecan to prevent recurrence in triple negative breast cancer (ASPRIA) [Internet]. clinicaltrials.gov"},{"key":"#cr-split#-1525_CR91.2","unstructured":"[cited 2024 Oct 31]. Report No.: NCT04434040. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04434040"},{"key":"1525_CR92","unstructured":"Study Details | Study of sacituzumab govitecan-hziy and pembrolizumab versus treatment of physician\u2019s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy (ASCENT-05\/AFT-65 OptimICE-RD\/NSABP B-63) | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05633654?term=NCT05633654&rank=1"},{"key":"1525_CR93","unstructured":"Study Details | A phase II study of neoadjuvant sacituzumab govitecan and pembrolizumab therapy for immunochemotherapy-resistant early-stage triple-negative breast cancer (TNBC) | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05675579?term=Sacituzumab&rank=41"},{"issue":"3","key":"1525_CR94","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","volume":"35","author":"LM Spring","year":"2024","unstructured":"Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B et al (2024) Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial\u2606. Ann Oncol 35(3):293\u2013301","journal-title":"Ann Oncol"},{"key":"1525_CR95","unstructured":"Study Details | Sequential therapies modeled on evolutionary dynamics for breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06409390?term=Sacituzumab&page=3&rank=110"},{"key":"1525_CR96","unstructured":"Study Details | A study evaluating the efficacy and safety of multiple treatment combinations in patients with metastatic or locally advanced breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03424005"},{"key":"1525_CR97","doi-asserted-by":"crossref","unstructured":"Schmid P, Loi S, Merino LD la C, Yerushalmi R, Im SA, Sonnenblick A et al (2024) 181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: a phase Ib\/II study of multiple treatment (tx) combinations in pts with locally advanced\/metastatic BC (LA\/mBC). ESMO Open [Internet]. [cited 2024 Nov 1];9. Available from: https:\/\/www.esmoopen.com\/article\/S2059-7029(24)00971-2\/fulltext","DOI":"10.1016\/j.esmoop.2024.103203"},{"key":"1525_CR98","unstructured":"Study Details | A safety study of SGN-LIV1A in breast cancer patients | ClinicalTrials.gov [Internet]. [cited 2024 Oct 4]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT01969643?term=NCT01969643&rank=1"},{"key":"1525_CR99","unstructured":"Seagen Inc. Single arm, open label phase 1b/2 Study of SGN-LIV1A in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer [Internet]. clinicaltrials.gov; 2024 Jul [cited 2024 Nov 1]. Report No.: NCT03310957. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03310957"},{"key":"1525_CR100","unstructured":"Study Details | I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01042379"},{"key":"1525_CR101","unstructured":"Study Details | A study of RC48-ADC for the treatment of locally advanced or metastatic breast cancer with low expression of HER2 | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04400695?term=RC48-ADC&page=4&rank=38#participation-criteria"},{"key":"1525_CR102","unstructured":"Study Details | RC48-ADC in HER2-low advanced breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05831878?term=Disitamab%20vedotin%20&page=1&rank=9"},{"key":"1525_CR103","unstructured":"Study Details | Disitamab vedotin (RC48) in hormone receptor positive, HER2-low metastatic breast cancer (the Rosy Trial) | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05904964"},{"key":"1525_CR104","unstructured":"Xijing Hospital. Phase II clinical study to evaluate the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC) for neoadjuvant treatment of breast cancer with positive HER2 expression (Seraph) [Internet]. clinicaltrials.gov; 2021 Nov [cited 2024 Nov 1]. Report No.: NCT05134519. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05134519"},{"key":"1525_CR105","unstructured":"Study Details | A study of U3-1402 (patritumab deruxtecan) in subjects with metastatic breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04699630?term=Patritumab%20Deruxtecan&rank=4"},{"key":"1525_CR106","doi-asserted-by":"crossref","unstructured":"Pistilli B, Ibrahimi N, Lacroix-Triki M, D\u2019Hondt V, Vicier C, Frenel JS et al (2023) 189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01). ESMO Open [Internet]. [cited 2024 Oct 1];8(1). Available from: https:\/\/www.esmoopen.com\/article\/S2059-7029(23)00604-X\/fulltext","DOI":"10.1016\/j.esmoop.2023.101378"},{"issue":"35","key":"1525_CR107","doi-asserted-by":"publisher","first-page":"S357","DOI":"10.1016\/j.annonc.2024.08.288","volume":"1","author":"B Pistilli","year":"2024","unstructured":"Pistilli B, Pierotti L, Lacroix-Triki M, Vicier C, Frenel JS, D\u2019Hondt V et al (2024) 340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+\/HER2- advanced breast cancer (ABC). Ann Oncol 1(35):S357","journal-title":"Ann Oncol"},{"key":"1525_CR108","unstructured":"SOLTI Breast Cancer Research Group. A window-of-opportunity study of U3-1402, a HER3-targeting antibody-drug conjugate in operable breast cancer according to ERBB3 expression [Internet]. clinicaltrials.gov; 2023 Jun [cited 2024 Oct 26]. Report No.: NCT04610528. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04610528"},{"key":"#cr-split#-1525_CR109.1","unstructured":"Oliveira M, Pascual T, Villacampa G, Munoz M, Martorell AP, Lopez MEP et al (2023) 155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd"},{"key":"#cr-split#-1525_CR109.2","unstructured":"U3-1402) +\/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+\/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial. ESMO Open [Internet]. [cited 2024 Oct 1];8(1). Available from: https:\/\/www.esmoopen.com\/article\/S2059-7029(23)00720-2\/fulltext"},{"issue":"16_suppl","key":"1525_CR110","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2024.42.16_suppl.1020","volume":"42","author":"X Hu","year":"2024","unstructured":"Hu X, Wang L, Zhang J, Zhang Q, Ouyang Q, Wang X et al (2024) ACE-Breast-02: a pivotal phase II\/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). JCO 42(16_suppl):1020","journal-title":"JCO"},{"issue":"16_suppl","key":"1525_CR111","doi-asserted-by":"publisher","first-page":"TPS1123","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1123","volume":"42","author":"D Tripathy","year":"2024","unstructured":"Tripathy D, Ali K, Agrawal L, Ali SM, Blau S, Block M et al (2024) ACE-BREAST-03: a phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd). JCO 42(16_suppl):TPS1123","journal-title":"JCO"},{"issue":"4","key":"1525_CR112","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","volume":"11","author":"H Wang","year":"2019","unstructured":"Wang H, Yee D (2019) I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer. Curr Breast Cancer Rep 11(4):303\u2013310","journal-title":"Curr Breast Cancer Rep"},{"key":"1525_CR113","unstructured":"Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and\/or T-DXd, and\/or tucatinib-containing regimens. J Clin Oncol [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2022.40.16_suppl.TPS1112"},{"issue":"0","key":"1525_CR114","first-page":"JCO.24.00920","volume":"0","author":"A Bardia","year":"2024","unstructured":"Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S et al (2024) Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013negative breast cancer: primary results from TROPION-Breast01. JCO 0(0):JCO.24.00920","journal-title":"JCO"},{"key":"1525_CR115","unstructured":"Study Details | A phase-3, open-label, randomized study of Dato-DXd versus investigator\u2019s choice of chemotherapy (ICC) in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy (TROPION-Breast01) | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05104866?term=NCT05104866&rank=1"},{"key":"1525_CR116","unstructured":"Study Details | A study of Dato-DXd versus investigator\u2019s choice chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer, who are not candidates for PD-1\/PD-L1 inhibitor therapy (TROPION-Breast02) | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05374512?limit=50&term=NCT05374512&rank=1"},{"key":"1525_CR117","unstructured":"Study Details | A study of Dato-DXd with or without durvalumab versus investigator\u2019s choice of therapy in patients with stage I-III triple-negative breast cancer without pathological complete response following neoadjuvant therapy (TROPION-Breast03) | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05629585"},{"issue":"17_suppl","key":"1525_CR118","doi-asserted-by":"publisher","first-page":"LBA501","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA501","volume":"42","author":"RA Shatsky","year":"2024","unstructured":"Shatsky RA, Trivedi MS, Omene CO, Kalinsky K, Roussos Torres ET, Thomas B et al (2024) Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: results from the I-SPY2.2 trial. JCO 42(17_suppl):LBA501","journal-title":"JCO"},{"issue":"15_suppl","key":"1525_CR119","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1200\/JCO.2021.39.15_suppl.1023","volume":"39","author":"P Schmid","year":"2021","unstructured":"Schmid P, Im SA, Armstrong A, Park YH, Chung WP, Nowecki Z et al (2021) BEGONIA: Phase 1b\/2 study of durvalumab (D) combinations in locally advanced\/metastatic triple-negative breast cancer (TNBC)\u2014Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). JCO 39(15_suppl):1023","journal-title":"JCO"},{"key":"1525_CR120","unstructured":"AstraZeneca. A phase IB/II, 2-stage, open-label, multicenter study to determine the efficacy and safety of durvalumab (MEDI4736) + paclitaxel and durvalumab (MEDI4736) in combination with novel oncology therapies with or without paclitaxel for first-line metastatic triple negative breast cancer [Internet]. clinicaltrials.gov; 2024 Aug [cited 2024 Oct 30]. Report No.: NCT03742102. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03742102"},{"key":"1525_CR121","unstructured":"Study Details | A phase III study of Dato-DXd with or without durvalumab compared with investigator\u2019s choice of chemotherapy in combination with pembrolizumab in patients with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06103864?term=Dato-DXd&rank=10#collaborators-and-investigators"},{"key":"1525_CR122","unstructured":"Study Details | A study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06508216?term=Dato-DXd&page=2&rank=14"},{"key":"1525_CR123","unstructured":"Study Details | DATO-BASE: DATOpotamab-deruxtecan for breast cancer brain metastases | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06176261?term=Dato-DXd&page=3&rank=22"},{"key":"1525_CR124","unstructured":"Study Details | SHR-A1811 in combination with adebrelimab for the treatment of HER2 low-expressing metastatic breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06411457?term=SHRA1811&rank=6"},{"key":"1525_CR125","unstructured":"Study Details | SHR-A1811 versus investigator\u2019s chemotherapy in recurrent\/metastatic breast cancer clinical trial | ClinicalTrials.gov [Internet]. [cited 2024 Oct 4]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05814354?term=NCT05814354%20&intr=Sacituzumab%20govitecan&rank=1"},{"key":"1525_CR126","unstructured":"Study Details | A study of SHR-A1811 combined with capecitabine in treatment of unresectable or metastatic breast cancer with low HER2 expression. | ClinicalTrials.gov [Internet]. [cited 2024 Oct 4]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05845138?term=NCT05845138&intr=Sacituzumab%20govitecan&rank=1"},{"key":"1525_CR127","unstructured":"Study Details | A phase Ib\/II study of SHR-A1811 injection in breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05353361?term=SHRA1811&rank=3"},{"key":"1525_CR128","unstructured":"Study Details | Study of SHR-A1811 in HER2-expression advanced breast cancer with brain metastases | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05769010?term=SHRA1811&rank=16"},{"key":"1525_CR129","unstructured":"Study Details | A study of SHR-A1811 monotherapy or combined with pyrotinib maleate as neoadjuvant treatment in HER2-positive breast cancer patients | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05635487?term=SHRA1811&rank=5"},{"issue":"35","key":"1525_CR130","doi-asserted-by":"publisher","first-page":"S331","DOI":"10.1016\/j.annonc.2024.08.218","volume":"1","author":"CG Liu","year":"2024","unstructured":"Liu CG, Niu N, Qiu F, Gu X, Zheng X, Guo J et al (2024) 276P SHR-A1811 in combination with pyrotinib as neoadjuvant treatment for HER2-positive breast cancer (HER2+ BC): preliminary results from MUKDEN 07. Ann Oncol 1(35):S331","journal-title":"Ann Oncol"},{"key":"1525_CR131","unstructured":"Study Details | A study of SHR-A1811 as neoadjuvant treatment for patients with HR-positive, low HER2 expression breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05911958?term=SHRA1811&rank=2"},{"issue":"16_suppl","key":"1525_CR132","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/JCO.2024.42.16_suppl.104","volume":"42","author":"B Xu","year":"2024","unstructured":"Xu B, Yin Y, Fan Y, Ouyang Q, Song L, Wang X et al (2024) Sacituzumab tirumotecan (SKB264\/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): results from the phase III OptiTROP-Breast01 study. JCO 42(16_suppl):104","journal-title":"JCO"},{"key":"1525_CR133","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. A randomized, controlled, open-label, multi-center phase III clinical trial of SKB264 for injection versus investigator selected regimens in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have failed second-line or above prior standard of care [Internet]. clinicaltrials.gov; 2023 Oct [cited 2024 Oct 28]. Report No.: NCT05347134. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05347134"},{"key":"1525_CR134","unstructured":"Study Details | A study of sacituzumab tirumotecan (MK-2870) as a single agent and in combination with pembrolizumab (MK-3475) versus treatment of physician\u2019s choice in participants with HR+\/HER2- unresectable locally advanced or metastatic breast cancer (MK-2870-010) | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06312176?term=Sacituzumab&page=2&rank=56"},{"key":"1525_CR135","unstructured":"Study Details | A study to evaluate the safety, tolerability, and efficacy of MORAb-202 (herein referred to as farletuzumab ecteribulin), a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC) in participants with selected tumor types | ClinicalTrials.gov [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04300556?term=NCT04300556&rank=1"},{"issue":"15_suppl","key":"1525_CR136","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1200\/JCO.2021.39.15_suppl.1022","volume":"39","author":"J Wang","year":"2021","unstructured":"Wang J, Liu Y, Zhang Q, Feng J, Fang J, Chen X et al (2021) RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies. JCO 39(15_suppl):1022","journal-title":"JCO"},{"key":"1525_CR137","unstructured":"Study Details | Dose-expansion modular study to explore the safety, tolerability, and anti-tumor activity of HER3- DXd monotherapy and combinations in patients with inoperable advanced breast cancer (ABC) after progression on T-DXd | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06298084?term=Patritumab%20Deruxtecan&page=2&rank=16"},{"issue":"32","key":"1525_CR138","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1016\/j.annonc.2021.08.563","volume":"1","author":"R Bartsch","year":"2021","unstructured":"Bartsch R, Berghoff AS, Furtner J, Bergen ES, Roider-Schur S, Marhold M et al (2021) 280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: results from the first stage of the phase II TUXEDO-1 trial. Ann Oncol 1(32):S486","journal-title":"Ann Oncol"},{"key":"1525_CR139","unstructured":"Study Details | Phase II study of Dato-DXd in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05866432?term=Dato-DXd&page=3&rank=25"},{"issue":"83","key":"1525_CR140","doi-asserted-by":"publisher","first-page":"CT175","DOI":"10.1158\/1538-7445.AM2023-CT175","volume":"14","author":"H Yao","year":"2023","unstructured":"Yao H, Yan M, Tong Z, Wu X, Ryu MH, Kim J et al (2023) Abstract CT175: safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing\/mutated advanced solid tumors: a global phase 1, multi-center, first-in-human study. Cancer Res 14(83):CT175","journal-title":"Cancer Res"},{"issue":"14","key":"1525_CR141","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","volume":"27","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Sato J, Tamura K et al (2021) First-in-human phase 1 study of MORAb-202, an antibody\u2013drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-\u03b1\u2013positive advanced solid tumors. Clin Cancer Res 27(14):3905\u20133915","journal-title":"Clin Cancer Res"},{"key":"1525_CR142","unstructured":"Study Details | Study of antibody drug conjugate in patients with advanced breast cancer expressing HER2 | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT02952729?term=XMT-1522&rank=1"},{"key":"1525_CR143","unstructured":"Study Details | A study of XMT-2056 in advanced\/recurrent solid tumors that express HER2 | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05514717?term=XMT-2056&rank=1"},{"key":"1525_CR144","unstructured":"Study Details | A dose finding study of ZW49 in patients with HER2-positive cancers | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03821233"},{"key":"1525_CR145","unstructured":"Study Details | A study of BB-1701 in previously treated participants with human epidermal growth factor receptor 2 (HER2)-positive or HER2-low unresectable or metastatic breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06188559?term=BB-1701&rank=2"},{"key":"1525_CR146","unstructured":"Study Details | A study of SI-B003 or BL-B01D1+SI-B003 in Patients with unresectable locally advanced or recurrent metastatic HER2 negative breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06042894?term=B003&page=1&rank=2"},{"key":"1525_CR147","unstructured":"Study Details | Safety of GQ1001 in adult patients with HER2-positive advanced solid tumors | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04450732?term=GQ1001&rank=1"},{"key":"1525_CR148","unstructured":"Study Details | GQ1001 combined with pyrotinib for treatment with HER2 positive metastatic breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05575804?term=GQ1001&rank=2"},{"key":"1525_CR149","unstructured":"Ozmosi | HS-630 drug profile [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/pryzm.ozmosi.com\/product\/32608"},{"key":"1525_CR150","unstructured":"Delving into the latest updates on GB-251 with synapse [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/synapse.patsnap.com\/drug\/70e57a7a8c6d4a06bd27b1d0273bbe55"},{"key":"1525_CR151","unstructured":"Study Details | Safety, tolerability, and pharmacokinetic (PK) study of DHES0815A in participants with human epidermal growth factor receptor (HER)2-positive breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03451162?term=DHES0815A&rank=1#study-plan"},{"key":"1525_CR152","unstructured":"A Phase II clinical study to evaluate the efficacy and safety of a recombinant humanized anti-HER2 monoclonal antibody-Tub114 conjugate (DX126\u2013262) in patients with HER2-positive unresectable locally advanced or recurrent metastatic breast cancer [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/clin.larvol.com\/trial-detail\/CTR20211871"},{"key":"1525_CR153","unstructured":"Study Details | A study of DP303c in patients with HER2-positive advanced solid tumors | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05810103?term=DP303c&rank=4"},{"key":"1525_CR154","unstructured":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd. A multicentre, randomized, open-label, controlled phase \u0428 clinical study to evaluate the efficacy and safety of DP303c versus trastuzumab emtansine in patients with HER2-positive advanced breast cancer [Internet]. clinicaltrials.gov; 2024 May [cited 2024 Oct 22]. Report No.: NCT06313086. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06313086"},{"key":"1525_CR155","unstructured":"Sichuan Baili Pharmaceutical Co., Ltd. A randomized controlled phase III clinical study comparing BL-M07D1 with T-DM1 in patients with unresectable locally advanced or metastatic HER2-positive breast cancer [Internet]. clinicaltrials.gov; 2024 Jul [cited 2024 Oct 22]. Report No.: NCT06316531. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06316531"},{"key":"1525_CR156","unstructured":"Study Details | A study of MRG002 in the treatment of patients with HER2-positive unresectable locally advanced or metastatic breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04924699?limit=50&term=MRG002&rank=10"},{"issue":"4","key":"1525_CR157","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.clbc.2021.11.006","volume":"22","author":"S Chiradoni Thungappa","year":"2022","unstructured":"Chiradoni Thungappa S, Maksud T, Raut N, Nagarkar R, Batra U, Kumar S et al (2022) Comparison of the efficacy, safety, pharmacokinetic and immunogenicity of UJVIRA (ZRC-3256, trastuzumab emtansine) with the kadcyla (trastuzumab emtansine) in the treatment of HER2-positive metastatic breast cancer: a randomized, open-label, multicenter study in India. Clin Breast Cancer 22(4):300\u2013307","journal-title":"Clin Breast Cancer"},{"key":"1525_CR158","unstructured":"Study Details | FS-1502 versus T-DM1 for HER2-positive unresectable locally advanced or metastatic breast cancer | ClinicalTrials.gov [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05755048?limit=50&term=FS-1502&rank=2"},{"key":"1525_CR159","unstructured":"DualityBio Inc. A phase III, multicenter, open-label, randomized study to compare DB-1303 versus T-DM1 in patients with HER2-positive unresectable/metastatic breast cancer who have been treated with trastuzumab and a taxane (Dynasty-Breast01) [Internet]. clinicaltrials.gov; 2024 Feb [cited 2024 Oct 23]. Report No.: NCT06265428. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06265428"},{"key":"1525_CR160","unstructured":"Phase III study of TAA013 versus lapatinib combined with capecitabine in patients with HER2-positive breast cancer [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/clin.larvol.com\/trial-detail\/CTR20200806"},{"issue":"6","key":"1525_CR161","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/CAD.0000000000001456","volume":"34","author":"Y Li","year":"2023","unstructured":"Li Y, Qi L, Wang Y, Zhao X, Lv S, Feng Y et al (2023) Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study. Anticancer Drugs 34(6):763\u2013774","journal-title":"Anticancer Drugs"},{"issue":"9816","key":"1525_CR162","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379(9816):633\u2013640","journal-title":"Lancet"},{"issue":"12","key":"1525_CR163","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","volume":"29","author":"P Conte","year":"2018","unstructured":"Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O et al (2018) Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study\u2021. Ann Oncol 29(12):2328\u20132333","journal-title":"Ann Oncol"},{"key":"1525_CR164","unstructured":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics - PubMed [Internet]. [cited 2024 Oct 4]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26182432\/"},{"issue":"4_Supplement","key":"1525_CR165","doi-asserted-by":"publisher","first-page":"P5-16\u201315","DOI":"10.1158\/1538-7445.SABCS21-P5-16-15","volume":"82","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Bardia A, Loirat D, Tolaney SM, Punie K, Oliveira M et al (2022) Abstract P5\u201316\u201315: post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). Cancer Res 82(4_Supplement):P5-16\u201315","journal-title":"Cancer Res"},{"issue":"10390","key":"1525_CR166","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G et al (2023) Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401(10390):1773\u20131785","journal-title":"Lancet"},{"key":"1525_CR167","unstructured":"Iyer A. Tempus. 2024 [cited 2025 Mar 6]. Multicenter retrospective cohort study of the sequential use of antibody drug conjugates trastuzumab deruxtecan & sacituzumab govitecan in patients with HER2 low metastatic breast cancer: a subgroup analysis of next generation sequencing results. Available from: https:\/\/www.tempus.com\/publications\/multicenter-retrospective-cohort-study-of-the-sequential-use-of-antibody-drug-conjugates-trastuzumab-deruxtecan-sacituzumab-govitecan-in-patients-with-her2-low-metastatic-breast-cancer-a-subgroup-a\/"},{"issue":"4","key":"1525_CR168","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","volume":"131","author":"F Poumeaud","year":"2024","unstructured":"Poumeaud F, Morisseau M, Cabel L, Gon\u00e7alves A, Rivier C, Tr\u00e9dan O et al (2024) Efficacy of administration sequence: sacituzumab govitecan and trastuzumab deruxtecan in HER2-low metastatic breast cancer. Br J Cancer 131(4):702\u2013708","journal-title":"Br J Cancer"},{"issue":"16_suppl","key":"1525_CR169","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1200\/JCO.2023.41.16_suppl.1022","volume":"41","author":"RO Abelman","year":"2023","unstructured":"Abelman RO, Spring L, Fell GG, Ryan P, Vidula N, Medford AJ et al (2023) Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study. JCO 41(16_suppl):1022\u20131022","journal-title":"JCO"},{"issue":"12","key":"1525_CR170","doi-asserted-by":"publisher","first-page":"10211","DOI":"10.3390\/curroncol30120743","volume":"30","author":"MA Fenton","year":"2023","unstructured":"Fenton MA, Tarantino P, Graff SL (2023) Sequencing antibody drug conjugates in breast cancer: exploring future roles. Curr Oncol 30(12):10211\u201310223","journal-title":"Curr Oncol"},{"key":"1525_CR171","doi-asserted-by":"crossref","unstructured":"Breast Cancer Brain Metastasis\u2014Overview of Disease State, Treatment Options and Future Perspectives [Internet]. [cited 2024 Oct 10]. Available from: https:\/\/www.mdpi.com\/2072-6694\/13\/5\/1078","DOI":"10.3390\/cancers13051078"},{"issue":"12","key":"1525_CR172","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","volume":"121","author":"A Darlix","year":"2019","unstructured":"Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M et al (2019) Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer 121(12):991\u20131000","journal-title":"Br J Cancer"},{"issue":"1","key":"1525_CR173","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-014-3090-8","volume":"147","author":"N Niikura","year":"2014","unstructured":"Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K-i et al (2014) Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat 147(1):103\u201312","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1525_CR174","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP (2023) Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel) 15(3):713","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1525_CR175","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M (2018) Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs 36(1):121\u2013135","journal-title":"Invest New Drugs"},{"key":"1525_CR176","doi-asserted-by":"crossref","unstructured":"D\u2019Arienzo A, Verrazzo A, Pagliuca M, Napolitano F, Parola S, Viggiani M et al (2023) Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. eClinicalMedicine [Internet]. [cited 2025 Mar 5];62. Available from: https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(23)00290-0\/fulltext","DOI":"10.1016\/j.eclinm.2023.102113"},{"issue":"5","key":"1525_CR177","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.clbc.2024.04.003","volume":"24","author":"R Pedersini","year":"2024","unstructured":"Pedersini R, Buffoni M, Petrelli F, Ghidini A, di Mauro P, Amoroso V et al (2024) Gastrointestinal toxicity of antibody drug conjugates (ADCs) in metastatic breast cancer: a pooled analysis. Clin Breast Cancer 24(5):411\u2013420","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"1525_CR178","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy H (2016) Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8(4):659\u2013671","journal-title":"MAbs"},{"issue":"2","key":"1525_CR179","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","volume":"32","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fern\u00e1ndez-Pe\u00f1as P, Santini D et al (2021) Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines\u2606. Ann Oncol 32(2):157\u2013170","journal-title":"Ann Oncol"},{"issue":"5","key":"1525_CR180","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.abd.2020.03.005","volume":"95","author":"G de Barros Silva","year":"2020","unstructured":"de Barros Silva G, Ciccolini K, Donati A, van den Hurk C (2020) Scalp cooling to prevent chemotherapy-induced alopecia. An Bras Dermatol 95(5):631\u20137","journal-title":"An Bras Dermatol"},{"issue":"41","key":"1525_CR181","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361","journal-title":"Eur Heart J"},{"issue":"10","key":"1525_CR182","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","volume":"31","author":"B Jordan","year":"2020","unstructured":"Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31(10):1306\u20131319","journal-title":"Ann Oncol"},{"key":"1525_CR183","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","volume":"106","author":"SM Swain","year":"2022","unstructured":"Swain SM, Nishino M, Lancaster LH, Li BT, Nicholson AG, Bartholmai BJ et al (2022) Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 106:102378","journal-title":"Cancer Treat Rev"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01525-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01525-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01525-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:27:01Z","timestamp":1757172421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01525-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":193,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01525-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}